A Multicenter, One Group, Open-label Study to Evaluate the Safety and Efficacy of Pletaal(Cilostazol) as BID for up to 24 Weeks Exposure in Subjects With Vasospastic Angina (STELLA Extension)

Trial Profile

A Multicenter, One Group, Open-label Study to Evaluate the Safety and Efficacy of Pletaal(Cilostazol) as BID for up to 24 Weeks Exposure in Subjects With Vasospastic Angina (STELLA Extension)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Cilostazol (Primary)
  • Indications Angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms STELLA_Ext
  • Sponsors Korea Otsuka Pharmaceutical
  • Most Recent Events

    • 28 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 04 Sep 2014 Modified inclusion and exclusion criteria as reported in ClinicalTrials.gov record.
    • 25 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top